Cleveland BioLabs, Inc. (NASDAQ: CBLI) has opened the U.S. office of Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures, LLC. The opening of this office triggers the first tranche consisting of a $5.7 million investment into Incuron. The initial development plan for Incuron is to complete formal preclinical studies, submit an IND to the FDA and advance the next generation of Curaxin compounds to clinical trials.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
